Nucleotide analog inhibitors, including broad-spectrum remdesivir and favipiravir, have
shown promise in in vitro assays and some clinical studies for COVID-19 treatment, this …

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
developed into an unprecedented global pandemic. Nucleoside analogs, such as …

Abstract A novel coronavirus (2019-nCoV) outbreak has caused a global pandemic resulting
in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent …

Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control
this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS …

Remdesivir is a nucleoside analog approved by the US FDA for treatment of COVID-19.
Here, we present a 3.9-Å-resolution cryo-EM reconstruction of a remdesivir-stalled RNA …

The rapid global emergence of SARS-CoV-2 has been the cause of significant health
concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA …

The replication transcription complex (RTC) from the virus SARS-CoV-2 is responsible for
recognizing and processing RNA for two principal purposes. The RTC copies viral RNA for …

Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The
active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA …

Non-structural proteins (nsp) constitute the SARS-CoV-2 replication and transcription
complex (RTC) to play a pivotal role in the virus life cycle. Here we determine the atomic …

COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
and is currently being treated using Remdesivir, a nucleoside analog that inhibits the RNA …